Advertisement

U.S. markets closed

S&P Futures
4,480.25
+2.75(+0.06%)
Dow Futures
35,132.00
-1.00(-0.00%)
Nasdaq Futures
15,302.25
+11.75(+0.08%)
Russell 2000 Futures
2,263.30
-1.40(-0.06%)
Crude Oil
82.44
0.00(0.00%)
Gold
1,772.30
+6.60(+0.37%)

Advertisement

CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

2.7200-0.0400 (-1.45%)

At close: 4:00PM EDT

2.7900 +0.07 (+2.57%)
After hours: 06:06PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	2.7600
Open	2.8300
Bid	2.7000 x 1000
Ask	2.7100 x 1000
Day's Range	2.6800 - 2.8400
52 Week Range	2.1500 - 4.1300
Volume	752,475
Avg. Volume	767,056

Market Cap	253.803M
Beta (5Y Monthly)	0.76
PE Ratio (TTM)	N/A
EPS (TTM)	-0.7970
Earnings Date	Nov 08, 2021 - Nov 12, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	7.28

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTIC

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

CTI BioPharma Corp.
Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Rating
Fair Value
Economic Moat
8 days agoMorningstar

All

News

Press Releases

Research Reports

PR Newswire
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on October 14, 2021, in accordance
- CytomX Therapeutics Announces New Employment Inducement Grants
  GlobeNewswire
- Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
  GlobeNewswire
Insider Monkey
10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital
In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. If you want to skip our detailed analysis of Stonepine Capital’s history, investment philosophy, and hedge fund preference, go directly to 5 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital. Timothy Lynch is […]
Zacks
CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study
CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.